DNA vs RGNX

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.

RGNX exhibits significant financial fragility, evidenced by a weak Piotroski F-Score of 3/9 and a lack of deterministic value markers like the Graham Number. While the company shows strong top-line revenue growth of 43%, this is offset by severe profitability deficits, including a profit margin of -113.75% and consistent earnings misses over the last four quarters. The stark divergence between the current price ($9.49) and the analyst target ($27.82) suggests a speculative valuation based on future pipeline success rather than current fundamentals. High debt-to-equity (2.54) and bearish insider sentiment further compound the risk profile.